Context: Abnormal glucagon concentrations contribute to hyperglycemia, but the mechanisms of a-cell dysfunction in prediabetes are unclear.
I
n 1975, Unger and Orci (1) described type 2 diabetes mellitus as a bihormonal disease characterized by defective insulin secretion and hyperglucagonemia. The combination of these defects results in hyperglycemia. Indeed, in the presence of delayed and decreased insulin secretion, impaired glucagon suppression contributes to hyperglycemia in health (2) and in type 2 diabetes (3). People with type 2 diabetes also exhibit impaired suppression of glucagon in response to insulin administration (4) . Despite substantial progress in understanding the changes in b-cell function that contribute to impaired glucose tolerance and the pathogenesis of type 2 diabetes (5), the mechanisms leading to a-cell dysfunction and their subsequent contribution to impaired glucose tolerance remains uncertain (6, 7) .
In vitro studies have characterized a complex system of a-cell regulation that includes various paracrine mediators (8) (9) (10) (11) (12) , autonomic input (13) , and circulating hormones (14) . In humans, hyperglucagonemia has been associated with impaired insulin secretion (15) , although some evidence suggests that this is not a causal relationship (16) . In vivo, experiments using an oral or an isoglycemic intravenous glucose challenge suggested that decreased insulin secretion, impaired insulin action (S i ), impaired incretin effect, or a-cell insensitivity to incretin hormones contributes to impaired postprandial suppression of glucagon (17, 18) . More recently, Faerch et al. (19) reported that impaired S i is associated with higher fasting glucagon concentrations and higher postprandial (30 minutes after an oral challenge) glucagon concentrations.
With the increasing prevalence of type 2 diabetes mellitus and prediabetes, a greater understanding of the characteristics associated with abnormal a-cell function may provide insight into the contribution of glucagon to the progression of prediabetes to diabetes (20) . This may be especially relevant given the advent of therapies that specifically target glucagon signaling for the treatment or prevention of type 2 diabetes (21). We therefore examined fasting and postprandial glucagon concentrations in a large cohort of nondiabetic participants to determine whether changes in fasting glucagon concentrations are associated with alterations in insulin secretion and action.
We report that fasting glucagon concentrations are inversely associated with S i and are not associated with indices of b-cell function; indeed, they are positively associated with fasting insulin and C-peptide concentrations. In a subset of 120 participants, induction of acute insulin resistance by elevation of circulating free fatty acids (FFAs) increased fasting and nadir glucagon concentrations. Taken together, these data suggest that defects in S i impair a-cell function and increase fasting glucagon concentrations.
Research Design and Methods

Participants
The volunteers in this study participated in previously published studies, during which they underwent a standardized seven-sample, 2-hour, 75-g oral glucose tolerance test, as previously described (22, 23) , together with measurement of body composition using dual-energy x-ray absorptiometry (DPX scanner; Lunar, Madison, WI) at the time of screening. Glucagon was measured at the time of study in both cohorts (23, 24) . The studies were performed after approval by the Mayo Institutional Review Board and informed, written consent was obtained. Participants were not taking medications that could affect glucose metabolism and had no history of chronic illness or upper gastrointestinal surgery. Participants were otherwise in good health, were at a stable weight, and did not engage in regular vigorous exercise. All participants were instructed to follow a weight-maintenance diet containing 55% carbohydrate, 30% fat, and 15% protein for at least 3 days before the study.
Experimental design: acute change in S i
Participants from one of the cohorts were also studied on two additional occasions in random order, as previously described (23) . On one occasion, participants received an infusion of Intralipid (Baxter Healthcare, Deerfield, IL) and heparin to raise FFA concentrations; on the other occasion, glycerol was infused at a rate of 5 mmol/kg/min (to match the amount of glycerol present in the Intralipid infused during the FFA study day). On each occasion, participants were admitted to the Clinical Research Unit at 1700 on the day before study. At 1800 they consumed a standard 10-kcal/kg meal (55% carbohydrate, 30% fat, 15% protein), followed by an overnight fast. At 0630 (2210 min) the following morning, a forearm vein was cannulated to allow infusions to be performed. In addition, a cannula was inserted retrogradely into a vein of the contralateral dorsum of the hand. This was placed in a heated Plexiglas box maintained at 55°C to allow sampling of arterialized venous blood.
At 0700 (2180 min), an infusion of Intralipid (20%, 0.011 mL/kg/min) and heparin (200 U prime, 0.2 U/kg/min continuous) was started, as previously described (25) . The infusion was continued till the end of study at 1600 (360 minutes). At 1000 (0 minutes), participants ingested a glucose drink (1 g/kg body weight). Blood samples were obtained at periodic intervals for hormone and substrate measurement during both the fasting and postprandial period.
Analytic techniques
Arterialized plasma samples were placed in ice, centrifuged at 4°C, separated, and stored at 220°C until assay. Plasma glucose concentrations were measured by using a glucose oxidase method Analox Instruments Inc., Lunenburg, MA; Yellow Springs Instruments, Yellow Springs, OH). Plasma insulin concentrations were measured by using a chemiluminescence assay with reagents (Access Assay; Beckman, Chaska, MN). Plasma C-peptide and glucagon concentrations were measured by radioimmunoassay (EMD Millipore, Billerica; MA).
Calculations
Integrated postprandial hormone concentrations-area above basal or area below basal (ABB) in the case of glucagon-were calculated by using the trapezoidal rule. Net S i was calculated from plasma insulin and glucose concentrations using the unlabeled oral minimal model (26) . b-Cell responsivity indexes were calculated from the plasma glucose and Cpeptide concentrations by using the oral C-peptide minimal model, incorporating age-associated changes in C-peptide kinetics (27) . The C-peptide minimal model assumes that insulin secretion is composed of a static (f s ) and dynamic (f d ) component. An index of total b-cell responsivity to glucose (F) is derived from both indices. Disposition indices were subsequently calculated as the product of F and S i , as reviewed previously (28) .
Statistical analysis
Across the quartiles of fasting and 2-hour glucose, there were significant differences in age, sex, and weight (data not shown). In addition, fasting glucagon concentrations were higher in men (88 6 3 in men vs 72 6 1 ng/L in women; P , 0.01). Consequently, in our subsequent multivariate regression analyses we incorporated age, sex and weight as covariates.
In the experiment where participants were studied on two occasions in the presence and absence of FFA elevation, differences between study days were tested by using a paired t test (parametric) or a Wilcoxon matched-pairs signed-rank test (nonparametric). All data are presented as mean 6 standard error of the mean unless otherwise noted. Multivariate analysis adjusting for the effects of age, sex, and weight (see the following sections) was performed in JMP Pro 11 (SAS Institute Inc., Cary, NC) and in Primer 5 (GraphPad Software, San Diego, CA). Residuals for the conditional logistic regression of a particular parameter with the covariates were used to confirm or refute the contribution of that parameter to variation in glucagon concentrations. A P value , 0.05 was considered to indicate a statistically significant difference.
Results
Participant characteristics
A total of 310 (134 men and 176 women) participants were studied. Their mean age was 57 6 1 years, their mean weight was 79 6 1 kg, and their mean fasting glucose level was 5.52 6 0.03 mmol/L.
Correlation of fasting glucagon with integrated ABB glucagon concentrations
Integrated postprandial suppression (ABB) of glucagon concentration in response to a 75-g oral glucose challenge was inversely correlated with fasting glucagon concentrations after adjustment for covariates (R 2 = 0.35; P , 0.01). On the other hand, ABB glucagon was not directly associated with fasting b-cell polypeptides or indexes of insulin secretion or action (independently of fasting glucagon). Hence, subsequent analyses focused on fasting glucagon concentrations.
Correlation of fasting glucagon with S i and fasting C-peptide concentrations Fasting glucagon concentrations (Fig. 1A) were inversely associated with S i before and after adjustment for covariates. The correlation was weak but significant (R 2 = 0.03; P , 0.01). Fasting insulin (data not shown) and C-peptide concentrations (Fig. 1B) were also weakly correlated (P , 0.01) with fasting glucagon concentrations both before and after adjustment for covariates.
Glucagon concentrations and relationship of fasting glucagon concentrations with S i in presence or absence of increased FFA concentrations
Intralipid and heparin infusion increased FFA approximately threefold (23) . This resulted in a significant decrease in S i (18 6 1 vs 13 6 1 10 24 dL/kg/min/mU/mL; P , 0.01) with an accompanying increase in both fasting (72 6 2 vs 79 6 2 ng/L; P , 0.01) and nadir (52 6 1 vs 56 6 2 ng/L; P , 0.01) glucagon concentrations ( Fig. 2A) . Fasting glucagon was weakly but significantly (P , 0.01) correlated with S i during both the glycerol and FFA study days (Fig. 2B ).
Discussion
People with type 2 diabetes have impaired postprandial suppression of glucagon (29) . It generally has been assumed that this is a consequence of impaired insulin secretion (4). However, Faerch et al. (19) recently reported that impaired S i (but not insulin secretion) is associated with both higher fasting and 30-minute postprandial concentrations of glucagon, suggesting that a-cell function may be modulated by alterations in S i . S i in that study was assessed qualitatively by using ratios of insulin and glucose, an approach that has significant limitations (30) . Postprandial glucagon concentrations were measured only at 30 and 120 minutes. We previously used the oral minimal model to measure insulin secretion and action in these 310 nondiabetic participants, which provided us with an opportunity to independently assess the relationship between fasting and postprandial glucagon concentrations with these indices. These data indicate that a decrease in S i is weakly associated with higher fasting glucagon concentrations (Fig. 1A) . On the other hand, indices of b-cell function, such as responsivity to glucose (F), are not associated (R 2 = 0.001) with glucagon concentrations. In fact, fasting glucagon concentrations are weakly, but positively, correlated with fasting insulin and C-peptide concentrations (Fig. 1B) .
Fasting insulin concentrations or the ratio of fasting insulin to fasting glucose concentrations are often used as a surrogate of insulin resistance (19) . Therefore, the observation that fasting glucagon is negatively correlated with S i and positively correlated with fasting insulin and C-peptide is consistent with surrogates of S i , such as the homeostatic model assessment of insulin resistance, which suggest that an alteration in S i impairs regulation of the a cell. This conclusion is consistent with the observation that accumulation of ceramide in a cells slows the reduction of preproglucagon messenger RNA by insulin (31) . In addition, insulin-resistant mice exhibit high glucagon concentrations despite hyperinsulinemia (31).
An alternative explanation for these observations is that insulin secretion in the fasting state increases in response to rising glucagon concentrations so as to maintain euglycemia rather than solely due to a decrease in S i . To distinguish between these two possibilities, we used data from a subset of these participants (n = 120) who were studied on two occasions: in the presence or absence of acute FFA-induced insulin resistance. Despite increased insulin and C-peptide secretion, the FFA-induced decrease in S i resulted in an increase in fasting glucagon concentrations ( Fig. 2A) . Taken together, these data strongly imply that in nondiabetic humans, a-cell function is modulated directly or indirectly by the prevailing level of S i (Fig. 2) . These observations are in keeping with the conclusions of Ahrén and Larsson (15) , who reported that impaired glucagon suppression in people with impaired glucose tolerance correlated with decreased S i as measured by a euglycemic clamp. They are also congruent with those reported by Faerch et al. (19) .
Intriguingly, sex significantly influenced fasting and integrated postchallenge glucagon concentrations in this cohort. Men have consistently been shown to have higher fasting blood glucose concentrations compared with women (32, 33) , as also was observed in this cohort (data not shown). Although the effects of estrogen on a-cell function are unclear, the age of our cohort suggests that estrogen is unlikely to explain the sex-based differences in glucagon concentrations observed. Previously we examined the role of glucagon-like peptide-1 (GLP-1) in the pathogenesis of type 2 diabetes and prediabetes (24) . However, there was no relationship of glucagonlike peptide 1 concentrations with glucagon suppression. Intriguingly, fasting total and active glucagon-like peptide 1 were positively correlated with fasting glucagon concentrations, as has been reported previously (34). Although the current study has strengths, such as quantitative measures of insulin secretion and action, as well as the frequent sampling of glucose, glucagon, insulin, and C-peptide concentrations before and after glucose ingestion, important limitations need to be considered. Part of this cohort was recruited on the basis of genotype at rs7903146 in the TCF7L2 locus, which is independently associated with impaired glucagon suppression [but not with changes in fasting glucagon concentrations (23) ]. However, TCF7L2 does not alter S i and therefore would not explain the observed relationship of glucagon with S i (23, 35) . Given the effect of impaired S i on fasting glucagon concentrations, it is intriguing to speculate that the increased postprandial glucagon concentrations attributable to diabetes-associated variation at the TCF7L2 locus would interact with an environmentally associated (e.g., obesity) decrease in S i to magnify any underlying defects of b-cell and a-cell function (23) .
Absolute insulin deficiency as seen in type 1 diabetes is associated with hyperglucagonemia, and correction of insulin deficiency lowers glucagon concentrations (4). However, these conditions are not pertinent to people with prediabetes or type 2 diabetes. Previous work has suggested that in these populations impaired S i is associated with variation in glucagon concentrations (15, 19) . This is again the case in the current study and is supported by similar findings in insulin resistant animals (31) . The observation that fasting glucagon concentrations are inversely correlated with S i is bolstered by the increase in fasting glucagon concentrations in response to an FFA-induced decrease in S i . This strongly suggests that impaired S i is accompanied by, or causes dysregulation of, a-cell function in nondiabetic humans.
